-
公开(公告)号：EP3426687A1
公开(公告)日：2019-01-16
申请号：EP17708811.9
申请日：2017-03-06
发明人： TAVERNIER, Jan , VAN DER HEYDEN, José , DEVOOGDT, Nick , D'HUYVETTER, Matthias , KRASNIQI, Ahmet
IPC分类号： C07K16/28 , A61K51/10 , G01N33/574 , A61P35/00
-
公开(公告)号：EP3455245A2
公开(公告)日：2019-03-20
申请号：EP17727814.0
申请日：2017-05-12
发明人： KLEY, Nikolai , TAVERNIER, Jan , HUYGHE, Leander , CAUWELS, Anje
IPC分类号： C07K14/435
-
公开(公告)号：EP3411397A1
公开(公告)日：2018-12-12
申请号：EP17704207.4
申请日：2017-02-06
发明人： TAVERNIER, Jan , CAUWELS, Anje , KLEY, Nikolai , GERLO, Sarah
IPC分类号： C07K14/715 , C07K16/28
CPC分类号： C07K16/2851 , A61K38/00 , A61K39/395 , A61K2039/505 , A61K2039/57 , C07K14/00 , C07K14/7156 , C07K16/00 , C07K16/249 , C07K16/2815 , C07K16/2818 , C07K16/2827 , C07K16/2887 , C07K2317/31 , C07K2317/33 , C07K2317/622 , C07K2317/66 , C07K2317/90 , C07K2319/00 , Y02A50/412
摘要： The present invention relates, in part, to agents that bind Clec9Aand their use as diagnostic and therapeutic agents.The present invention further relates to pharmaceutical compositions comprising the Clec9A binding agents and their use in the treatment of various diseases.
-
公开(公告)号：EP3411065A1
公开(公告)日：2018-12-12
申请号：EP17703965.8
申请日：2017-02-06
发明人： KLEY, Nikolai , TAVERNIER, Jan , CAUWELS, Anje , GERLO, Sarah
CPC分类号： C07K16/2851 , A61K38/00 , A61K39/395 , A61K2039/505 , A61K2039/57 , C07K14/00 , C07K14/7156 , C07K16/00 , C07K16/249 , C07K16/2815 , C07K16/2818 , C07K16/2827 , C07K16/2887 , C07K2317/31 , C07K2317/33 , C07K2317/622 , C07K2317/66 , C07K2317/90 , C07K2319/00 , Y02A50/412
摘要： The present invention relates, in part, to agents that bind Clec9Aand their use as diagnostic and therapeutic agents.The present invention further relates to pharmaceutical compositions comprising the Clec9A binding agents and their use in the treatment of various diseases.
-
公开(公告)号：EP2804877B1
公开(公告)日：2018-08-22
申请号：EP13701014.6
申请日：2013-01-17
申请人： VIB vzw , Universiteit Gent , Centre National de la Recherche Scientifique , Université de Montpellier , Centre Hospitalier Régional Universitaire de Montpellier , Universität Osnabrück
CPC分类号： A61K38/212 , A61K47/6813 , C07K14/56 , C07K16/2827 , C07K16/2863 , C07K16/2869 , C07K16/2878 , C07K16/32 , C07K2317/22 , C07K2317/569 , C07K2317/622 , C07K2319/31 , C07K2319/74
摘要： This disclosure relates to a modified α-helical bundle cytokine, with reduced activity via an α-helical bundle cytokine receptor, wherein the α-helical bundle cytokine is specifically delivered to target cells. Preferably, the α-helical bundle cytokine is a mutant, more preferably it is a mutant interferon, with low affinity to the interferon receptor, wherein the mutant interferon is specifically delivered to target cells. The targeting is realized by fusion of the modified α-helical bundle cytokine to a targeting moiety, preferably an antibody. This disclosure relates further to the use of such targeted modified α-helical bundle cytokine to treat diseases. A preferred embodiment is the use of a targeted mutant interferon, to treat diseases, preferably viral diseases and tumors.
-
公开(公告)号：EP2681319B1
公开(公告)日：2016-12-14
申请号：EP12706065.5
申请日：2012-02-29
申请人： VIB VZW , Universiteit Gent
发明人： TAVERNIER, Jan , LIEVENS, Samuel
CPC分类号： C12N9/12 , C07K2319/00 , C12N15/1055 , C12N15/62 , C12Q1/485 , G01N33/542
-
公开(公告)号：EP3021865A1
公开(公告)日：2016-05-25
申请号：EP14741613.5
申请日：2014-07-18
申请人： VIB VZW , Universiteit Gent , Centre National de la Recherche Scientifique , Université Montpellier 2 , Centre Hospitalier Regional Universitaire De Montpellier
IPC分类号： A61K38/19 , A61K39/395
CPC分类号： C07K14/525 , A61K38/00 , A61K2039/505 , C07K16/2869 , C07K16/32 , C07K2317/569 , C07K2319/00 , C07K2319/74
摘要： The present invention relates to a modified cytokine of the TNF superfamily, with reduced activity to its receptor, wherein said modified cytokine is specifically delivered to target cells. Preferably, said modified cytokine is a single chain variant of the TNF superfamily, even more preferably, one or more of the chains carry one or more mutations, resulting in a low affinity to the receptor, wherein said mutant cytokine is specifically delivered to target cells. The targeting is realized by fusion of the modified cytokine of the TNF superfamily to a targeting moiety, preferably an antibody or antibody-like molecule. The invention relates further to the use of such targeted modified cytokine of the TNF superfamily to treat diseases.
摘要翻译： 本发明涉及TNF受体的活性降低的TNF超家族的修饰细胞因子，其中所述修饰的细胞因子被特异性递送至靶细胞。 优选地，所述修饰的细胞因子是TNF超家族的单链变体，甚至更优选地，一个或多个链携带一个或多个突变，导致对受体的低亲和力，其中所述突变细胞因子被特异性递送至靶细胞 。 靶向通过将TNF超家族的修饰的细胞因子融合到靶向部分，优选抗体或抗体样分子来实现。 本发明进一步涉及TNF超家族的这种靶向修饰的细胞因子的用途来治疗疾病。
-
公开(公告)号：EP1812038A1
公开(公告)日：2007-08-01
申请号：EP05813344.8
申请日：2005-11-16
申请人： VIB vzw , UNIVERSITEIT GENT
发明人： TAVERNIER, Jan , ZABEAU, Lennart
IPC分类号： A61K38/16 , A61K38/22 , A61K39/395
CPC分类号： C07K16/2869 , A61K38/1793 , C07K2317/22 , C07K2317/569 , C07K2317/76
摘要： The invention relates to a new type of leptin receptor antagonist, which is able to prevent leptin signaling without preventing the binding of leptin to the leptin binding domain. More specifically, the invention relates to the use of a part of the leptin receptor to prevent the leptin- dependent activation of the receptor, and by this the leptin induced signaling.
-
公开(公告)号：EP4059957A1
公开(公告)日：2022-09-21
申请号：EP22160584.3
申请日：2017-02-06
发明人： KLEY, Nikolai , TAVERNIER, Jan , VAN LINT, Sandra , CAUWELS, Anje
摘要： The present invention relates, in part, to bispecific chimeric proteins that find use in various immunotherapies based on various properties, including, for example, a dual immune cell recruitment and immune signal delivery function.
-
公开(公告)号：EP3577133A1
公开(公告)日：2019-12-11
申请号：EP18706967.9
申请日：2018-02-05
发明人： KLEY, Nikolai , TAVERNIER, Jan
IPC分类号： C07K14/555 , C07K16/28 , A61K39/00
-
-
-
-
-
-
-
-
-
搜索结果
41 条记录 (耗时 0.032 秒)
